Genprex, Inc. NASDAQ:GNPX received a third Fast Track Designation for Reqorsa® Immunogene Therapy from the (FDA) U.S. Food and Drug Administration, in combination with Tecentriq® for treatment of small cell lung cancer.
For More Info
compasslivemedia.com/gnpx